# A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

> **NCT02824458** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 246 (estimated)

## Conditions studied

- EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Gefitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02824458
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 246 (ESTIMATED)
- **Last updated:** 2016-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02824458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02824458, "A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT02824458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*